Zongertinib Gains Accelerated FDA Approval as First Oral Targeted Option for HER2-Mutant Lung Cancer

Pune, India | August 13, 2025 — The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), an oral kinase inhibitor. This new therapy targets adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. Patients must have previously undergone systemic therapy, and mutations should be confirmed using an FDA-approved test.

The Oncomine Dx Target Test by Life Technologies Corporation also received FDA approval as a companion diagnostic. This test identifies patients with HER2 TKD mutations who could benefit from zongertinib treatment.

The FDA based its decision on data from the Phase Ib Beamion LUNG-1 study (NCT04886804). Among participants who had platinum-based chemotherapy but no prior HER2-targeted therapy, zongertinib showed a 75% overall response rate (ORR). Additionally, 58% of these responses lasted at least six months. In a second group previously treated with both platinum chemotherapy and HER2-directed therapies, the ORR was 44%, with 27% maintaining responses beyond six months.

The treatment demonstrated a median progression-free survival (PFS) of 12.4 months and a median duration of response (DOR) of 14.1 months. These results suggest that many patients experience lasting clinical benefits.

Zongertinib dosing depends on body weight. Patients weighing less than 90 kg take 120 mg once daily. Those 90 kg or more receive 180 mg once daily. The medication can be taken with or without food and continues until disease progression or unacceptable side effects occur.

HER2 mutations appear in about 2% to 4% of NSCLC cases. These mutations often correlate with poor prognosis and limited treatment options. This approval emphasizes the value of comprehensive molecular testing, including next-generation sequencing (NGS), to detect actionable genetic changes and guide personalized treatment plans.

The FDA requires confirmatory evidence from the ongoing Phase III Beamion LUNG-2 trial (NCT06151574). This trial compares zongertinib with current standard therapies in a similar patient population to verify its clinical benefits.

This regulatory approval marks a major step forward in precision oncology. It provides a targeted treatment option for patients with HER2-mutant lung cancer, many of whom previously had few effective therapies available.